$STTK

SIEGALL CLAY B purchased $250K of STTK

SIEGALL CLAY B purchased 62,500 shares of Shattuck Labs, Inc. (STTK) at $4.00 ($0.25M total) on 2026-06-09.

Original reporting
SEC EDGAR · SIEGALL CLAY B
Published Jun 11, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STTK
Bullish
medium confidence
Mentioned
$STTK
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STTKBullishLow
01

Why it matters

A director’s open-market purchase (no 10b5-1 plan stated) adds incremental bullish sentiment, but it does not change known business fundamentals by itself.

02

Market read

Traders may treat the filing as a small sentiment input, but it is unlikely to be a primary driver versus upcoming company-specific catalysts.

03

What to watch

The article doesn’t disclose why the director bought or whether other insiders/large holders acted; without clinical/regulatory updates, price reaction may be muted.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-11; transaction dated 2026-06-09

Background

This is an SEC Form 4 insider transaction disclosure for Shattuck Labs, Inc. (STTK).

Company-level read

Ticker impact

$STTKBullishMedium confidence
Context

Director SIEGALL CLAY B bought 62,500 shares of Shattuck Labs at $4.00/share via an open-market purchase disclosed on Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional buys or company catalysts.

Evidence & confidence

Form 4 provides a new, primary-source transaction (new information), but insider buys alone rarely create durable repricing without accompanying operational/regulatory/clinical updates.

Market effects

No sector-wide read-across; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (tax/portfolio rebalancing) and may not signal improved fundamentals, especially without follow-through.

Key entities

  • Shattuck Labs, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • SIEGALL CLAY B

    Director who purchased 62,500 shares on 2026-06-09.

Related articles

$STTKMed

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

Shattuck Labs shares rose about 4.8% on Friday, closing near $7.43. The move followed an inaugural note from JPMorgan’s Brian Cheng, who rated STTK overweight and set a $10 price target. The note cited Shattuck’s lead IBD drug candidate SL-325, referencing recent healthy volunteer data on safety and target engagement.

$STTKMedAI 8/10

Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr

Shattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and said it will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant. The company expects about $75 million in gross proceeds and said the deal should close June 11. Underwriters have a 30-day option for up to 2.81 million additional shares.

$STTKMedAI 9/10

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs (NASDAQ: STTK) priced a public offering of 10,879,376 shares at $4.00 each and pre-funded warrants for up to 7,870,624 shares at $3.9999 each, with a $0.0001 exercise price. Gross proceeds are expected at about $75 million before underwriting costs. The deal is set to close June 11, 2026, with a 30-day option for 2,812,500 additional shares.

$STTKMedAI 9/10

Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr

Shattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant, according to the company. Gross proceeds are expected at about $75 million before fees. The deal is set to close June 11, with a 30-day option for up to 2.81 million additional shares.

$STTKMedAI 9/10

Shattuck Labs, Inc. Announces Proposed Public Offering

Shattuck Labs (NASDAQ: STTK) said it has commenced a proposed public offering of its common stock, or pre-funded warrants in lieu of stock for certain investors. The company expects to grant underwriters a 30-day option to buy up to an additional 15% of shares at the offering price. Terms and size are subject to market conditions.

$STTKMedAI 9/10

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

Shattuck Labs (NASDAQ: STTK) said it will host an investor call and webcast on June 8, 2026 at 8:00 a.m. ET to present Phase 1 clinical data for SL-325, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics and immunogenicity, plus a pipeline update. Management including CEO Taylor Schreiber and CFO Andrew Neill will present, followed by Q&A.